A Pullback Creates Four Setups
Thursday’s selloff knocked each of these candidates lower, producing four constructive setups in companies with catalysts still ahead of them.
Only one member of Thursday night’s Portfolio Armor Top Ten cleared our strict technical gate. It remains above its rising 50-day exponential moving average, its RSI has settled into our preferred range, and its Chartmill Technical, Setup and Fundamental ratings are all solid. It’s a biopharma royalty platform, so its upside comes from a broad portfolio of commercial and clinical assets rather than one make-or-break trial.
Three more opportunities came from our Multibaggers list, our source-of-alpha category for ideas from outside analysts whose records we track and who have had multiple, recent, 100%+ gainers. All three received fresh confirmation from our Trend & Consolidation screen. Their upcoming checkpoints include regulatory submissions, pivotal data, a major medical-conference presentation and first-in-human development work.
Fresh Signals, Familiar Theses
We already have exposure to two of today’s names, and we attempted entries in two of them earlier this week without getting filled. The overlap is deliberate but modest. One structure adds risk-defined exposure to an open thesis whose technical setup has improved substantially since our first entry; the two retries preserve the underlying theses while applying today’s prices and implied volatilities.
A fresh signal isn’t permission to chase. We repriced every leg under Black-Scholes, Bjerksund-Stensland and a Cox-Ross-Rubinstein binomial model. The two debit limits sit below all three current fair-value estimates. The two minimum credits are at least as favorable as the models say they should be.
The structures match the roadmaps. Two conventional four-leg combos cap both gain and loss. A hybrid sells unusually expensive nearer-dated call premium while retaining longer-dated exposure. The risk reversal provides long-dated, uncapped upside with a maximum loss that remains inside our normal risk budget.
Four Structures, One Price Discipline
Several of these option markets are extremely wide, and some of the quoted legs haven’t traded. It’s entirely possible that one or more orders won’t fill. That’s preferable to paying above fair value simply because the thesis is attractive.
Paid subscribers will find the four names, complete structures, maximum entry prices and exit plans below.
Today’s Top Names Trade
Biopharma royalties / diversified pipeline and earnings-growth theme.
RSI: 46; Chartmill Technical Rating: 9; Setup Rating: 8; Fundamental Rating: 6.
